Blog: Mar 2018


27 March 2018

The Centre will be closed on Good Friday 30th March and Easter Monday 2nd April

Carers Lunch Club

27 March 2018

MS Carers Lunch Club - 12.00 to 2:30 p.m. on the second Thursday of each month We welcome anyone who cares for someone with MS, so why not try a session or two with us.

Caroline Wyatt - My quest to stop MS in its tracks

23 March 2018

Source BBC: A year on from gruelling stem cell treatment for her multiple sclerosis, BBC correspondent Caroline Wyatt reveals what effect the potentially life-changing "reboot" of her immune system has had on her life.

BMSTC Go Monte Carlo raises a massive £11,610!

23 March 2018

We are happy to announce our Go Monte Carlo fundraising total.....£11,610.14!!!

MS drug hope

23 March 2018

Source BBC: MS drug hope for secondary-progressive stage. A study of a new drug to treat advanced cases of multiple sclerosis suggests it may be possible to delay progression of the disease in the short term, although the effects were small.

Reading Half Marathon

23 March 2018

Samantha Harper: The Reading Half Marathon and the Green Park Challenge have been a highlight of our event calendar for many years.

Do you suffer with pain?

22 March 2018

If you suffer from pain why not give APS pain management a go?

Don’t worry if you have never heard of APS (Action Potential Simulation) as it is a relatively new treatment available to target pain. It is a safe, non-invasive treatment: four electrodes are placed at target areas as decided in your own personalised treatment plan devised by a physiotherapist. Find out more here.

Can anyone help to dispose of some pallets?

21 March 2018

We have 4 wooden pallets that were used to deliver equipment to the centre.

Can anyone help to dispose of them for us? If you can help please email Pippa.

Thanks in advance for your help.

Daclizumab withdrawn from NHS after safety concerns

21 March 2018

Source MS Society:

Disease modifying therapy daclizumab (Zinbryta) has been withdrawn from sale worldwide. Its manufacturers took the decision after reports that a number of people taking the treatment developed serious inflammatory brain disorders.